Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | CTSC | P53634 | 14/20 | 0.52 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.47 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.47 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.47 |
| ▸ | CTSL | P07711 | 1/20 | 0.44 |
| ▸ | CTSS | P25774 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6897726 | 0.99 | CYP2C19 (0.51) | CYP2C19CTSCSLC1A3SLC1A2SLC1A1 | |
| SCHEMBL2058609 | 0.80 | CTSC (0.59) | CYP2C19CTSCSLC1A3SLC1A2SLC1A1 | |
| SCHEMBL1631750 | 0.80 | CTSC (0.59) | CYP2C19CTSCSLC1A3SLC1A2SLC1A1 | |
| SCHEMBL19699149 | 0.80 | CTSC (0.59) | CYP2C19CTSCSLC1A3SLC1A2SLC1A1 | |
| SCHEMBL288244 | 0.79 | CYP2C19 (0.70) | CYP2C19CTSCSLC1A3SLC1A2SLC1A1 | |
| SCHEMBL43292 | 0.79 | CYP2C19 (0.70) | CYP2C19CTSCSLC1A3SLC1A2SLC1A1 | |
| SCHEMBL43293 | 0.79 | CYP2C19 (0.70) | CYP2C19CTSCSLC1A3SLC1A2SLC1A1 | |
| SCHEMBL7599942 | 0.79 | CYP2C19 (0.49) | CYP2C19CTSCCTSSRAB9A | |
| Hydrochloric Acid SCHEMBL7066923 | 0.79 | CTSC (0.58) | CYP2C19CTSCSLC1A3SLC1A2SLC1A1 | |
| SCHEMBL20543720 | 0.79 | CTSC (0.55) | CYP2C19CTSCSLC1A3SLC1A2SLC1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6730784-B2 | AS THERAPEUTIC AGENTS FOR AUTOIMMUNE DISEASES SUCH AS RHEUMATOID ARTHRITIS | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2004-05-04 | — | — | US | disclosed |
| US-20020198376-A1 | Novel urea derivatives | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2002-12-26 | — | — | US | disclosed |
| US-6492370-B1 | Urea derivatives and pharmaceutical compositions thereof | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2002-12-10 | — | — | US | disclosed |
| EP-1072591-A1 | NOVEL UREA DERIVATIVES | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2001-01-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020198376-A1 | Novel urea derivatives | TNF, CTH, CFH | CYP2C19 3652/4885CTSC 2352/4885SLC1A3 3946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.